Clinical Trial Update: Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating ergocalciferol therapy in calcidiol-deficient hemodialysis patients who are receiving paricalcitol has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Vitamin Deficiency

Drugs mentioned

• Paricalcitol (paricalcitol)
• ergocalciferol (ergocalciferol)

Snippet

Sponsor: University of Utah | Conditions: Inflammation, Insulin Resistance | Phase 1 | Status: COMPLETED